Table 4.
Final multivariate Cox regression models for progression-free survival and overall survival for patients in the ALLR3 trial with late bone marrow relapses
| HR (95% CI) | p value | p value (joint test) | |||
|---|---|---|---|---|---|
| Imputation model (n=220) | |||||
| Progression-free survival | |||||
| Sex | |||||
| Men vs women | 1·60 (1·00–2·56) | 0·049 | .. | ||
| Drug | |||||
| Idarubicin vs mitoxantrone | 1·54 (0·96–2·47) | 0·072 | .. | ||
| Minimal residual disease* | |||||
| High vs low | 1·71 (1·05–2·78) | 0·031 | .. | ||
| Cytogenetic risk | |||||
| Standard vs intermediate | 0·74 (0·46–1·20) | 0·22 | 0·091 | ||
| High vs intermediate | 1·68 (0·76–3·73) | 0·20 | .. | ||
| NRAS | |||||
| Mutated vs wild type | 2·08 (1·06–4·13) | 0·036 | .. | ||
| Model performance | |||||
| C-index=0·68 | .. | .. | .. | ||
| Overall survival | |||||
| Sex | |||||
| Men vs women | 1·54 (0·88–2·70) | 0·14 | .. | ||
| Drug | |||||
| Idarubicin vs mitoxantrone | 1·36 (0·77–2·40) | 0·29 | .. | ||
| Minimal residual disease* | |||||
| High vs low | 2·42 (1·29–4·56) | 0·006 | .. | ||
| Cytogenetic risk | |||||
| Standard vs intermediate | 0·77 (0·43–1·38) | 0·38 | 0·084 | ||
| High vs intermediate | 2·04 (0·83–5·02) | 0·12 | .. | ||
| NRAS | |||||
| Mutated vs wild type | 2·27 (1·03–5·02) | 0·040 | .. | ||
| Model performance | |||||
| C-index=0·70 | .. | .. | .. | ||
| Available cases (n=118) | |||||
| Progression-free survival | |||||
| Sex | |||||
| Men vs women | 1·68 (0·90–3·13) | 0·10 | .. | ||
| Drug | |||||
| Idarubicin vs mitoxantrone | 1·34 (0·72–2·48) | 0·359 | .. | ||
| Minimal residual disease* | |||||
| High vs low | 2·00 (1·05–3·79) | 0·034 | .. | ||
| Cytogenetic risk | |||||
| Standard vs intermediate | 0·91 (0·49–1·71) | 0·77 | 0·63 | ||
| High vs intermediate | 1·55 (0·51–4·75) | 0·44 | .. | ||
| NRAS | |||||
| Mutated vs wild type | 1·27 (0·53–3·07) | 0·59 | .. | ||
| Model performance | |||||
| C-index=0·64 | .. | .. | .. | ||
| Overall survival | |||||
| Sex | |||||
| Men vs women | 1·87 (0·86–4·08) | 0·11 | .. | ||
| Drug | |||||
| Idarubicin vs mitoxantrone | 1·15 (0·54–2·49) | 0·72 | .. | ||
| Minimal residual disease* | |||||
| High vs low | 2·45 (1·08–5·56) | 0·032 | .. | ||
| Cytogenetic risk | |||||
| Standard vs intermediate | 1·03 (0·48–2·24) | 0·94 | 0·70 | ||
| High vs intermediate | 1·75 (0·46–6·67) | 0·41 | .. | ||
| NRAS | |||||
| Mutated vs wild type | 1·70 (0·63–4·57) | 0·30 | .. | ||
| Model performance | |||||
| C-index=0·65 | .. | .. | .. | ||
Patients who did not have successful induction (n=8) were excluded from the modelling, as end of induction minimal residual disease was included in imputed missing data.
*
Minimal residual disease was measured at the end of induction. High minimal residual disease defined as ≥10−4 cells. Low minimal residual disease defined as <10−4 cells.